ClinicalTrialsFinder
Not Yet RecruitingPhase 1ACTRN12610000950066

Fibrinolytic treatment of acute respiratory failure due to inflammatory lung injury

Fibrinolytic treatment of acute respiratory failure due to inflammatory lung injury to assess improvement in alveolar dead space and right ventricular function

Sponsor

St Vincent's Hospital

Enrollment

12 participants

Start Date

Dec 12, 2010

Study Type

Interventional

Conditions

acute respiratory failure due to inflammatory lung injury

Summary

Inflammatory insults including pneumonia, sepsis, aspiration, trauma, prolonged hypotension, cardiac surgery and pancreatitis can cause lung damage. One mechanism by which inflammation mediates lung injury is through deposition of fibrin in the pulmonary microcirculation. This study will investigate if limiting fibrin deposition through administration of tissue plasminogen activator reduces lung damage.

Eligibility

Sex: Both males and femalesMin Age: 15 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a clot-dissolving medication (alteplase) delivered directly to the lungs can help patients with severe breathing failure caused by lung inflammation. It is for patients aged 15 and older on a breathing machine with poor oxygen levels. People with bleeding disorders, brain injuries, recent surgery, or very poor survival outlook are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Administration of tissue plasminogen activator (t-PA) on one occasion. Dose escalation study The first 4 patients will receive 1. 10 mg bolus and 10 mg over 30 min. The second 4 patients

Administration of tissue plasminogen activator (t-PA) on one occasion. Dose escalation study The first 4 patients will receive 1. 10 mg bolus and 10 mg over 30 min. The second 4 patients will receive 2. 10 mg bolus and 20 mg over 30 min. The final 4 patients will receive 3. 10 mg bolus and 40 mg over 30 min.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000950066